by TractManager | May 21, 2018 | Emerging Technology Report
Aimovig is a novel monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. CGRP is involved in vasodilation and sensory transmission, and is a validated target that is believed to play a key role in migraine headache. Aimovig...
by TractManager | May 10, 2018 | Health Technology Assessment
Health Problem: Amputation presents a significant disability that can have profound physical, psychological, and vocational consequences in a person’s life. Approximately 50,000 people undergo an amputation of the upper or lower limb each year in the United States,...
by TractManager | May 9, 2018 | Health Technology Assessment
Health Problem: Joint contractures refer to a decreased range of motion (ROM) that impairs function. Contractures may occur with many different afflictions, including neurological conditions, joint trauma, or healing; contractures may also occur secondarily to...
by TractManager | May 9, 2018 | Health Technology Assessment
Health Problem: Joint contractures refer to a decreased range of motion (ROM) in diarthrodial (or movable) joints. Contractures may occur with joint disease, trauma, or healing, or secondarily to structural changes in muscle, tendons, ligaments, and/or skin that limit...
by TractManager | May 3, 2018 | Emerging Technology Report
Kymriah (tisagenlecleucel, formerly CTL019) is an autologous CAR T-cell therapy, a novel type of immunotherapy in which a patient’s own genetically altered immune cells are used to attack cancer cells. The FDA approved Kymriah in August 2017 for the treatment of...
Recent Comments